To view this email as a web page, click here.
Conference Coverage
 
 December 5, 2017
 
Restarting TNFi treatment after a break proves beneficial in psoriasis
Switching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Learn More.
 
ADVERTISEMENT
 
Hard-to-treat psoriasis cases respond to secukinumab
Secukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Learn More.
 
Promising results for risankizumab continue in phase 3 trials
Phase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Learn More.
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.